Advanced Glycation End Products and Receptors in Fuchs’ Dystrophy Corneas Undergoing Descemet’s Stripping with Endothelial Keratoplasty

• Published in: Ophthalmology (Rochester, Minn.) Vol. 114; no. 8; pp. 1453 - 1460
• Main Authors: Wang, Zhiyou, PhD, Handa, James T., MD, Green, W. Richard, MD, Stark, Walter J., MD, Weinberg, Robert S., MD, Jun, Albert S., MD, PhD
• Format: Journal Article
• Language: English
• Published: New York, NY Elsevier Inc 01.08.2007; Elsevier
• Subjects: Aged; Aged, 80 and over; Apoptosis; Biological and medical sciences; Corneal Transplantation - methods; Descemet Membrane - metabolism; Descemet Membrane - pathology; Descemet Membrane - surgery; Endothelium, Corneal - metabolism; Endothelium, Corneal - pathology; Endothelium, Corneal - transplantation; Female; Fuchs' Endothelial Dystrophy - metabolism; Fuchs' Endothelial Dystrophy - pathology; Fuchs' Endothelial Dystrophy - surgery; Galectin 3 - metabolism; Glycation End Products, Advanced - metabolism; Humans; Immunoenzyme Techniques; Male; Medical sciences; Middle Aged; Miscellaneous; Ophthalmology; Oxidative Stress; Prospective Studies; Receptor for Advanced Glycation End Products; Receptors, Immunologic - metabolism; Tissue Donors; Stripping; Cornea; Treatment; Keratoplasty; Surgery; Dystrophy; Ophthalmology
• ISSN: 0161-6420; 1549-4713
• DOI: 10.1016/j.ophtha.2006.10.049

Purpose To describe the histopathologic features of Descemet’s membrane (DM) obtained from Fuchs’ endothelial corneal dystrophy (FECD) corneas undergoing Descemet’s stripping with endothelial keratoplasty (DSEK) and to assess the presence of advanced glycation end products (AGEs) and their receptors in FECD endothelium and DM. Design Prospective observational case series. Participants Five eyes of 5 patients undergoing DSEK for FECD and 4 normal control eyebank corneas. Methods Descemet’s membrane and corneal endothelium from FECD patients undergoing DSEK were assessed with hematoxylin–eosin staining and immunohistochemistry for AGEs, receptor of AGEs (RAGE), and galectin 3 (AGE-R3). Main Outcome Measures Histopathologic abnormalities and presence of AGEs, RAGE, and AGE-R3 in DSEK specimens. Results Histopathologic assessment of DSEK specimens from FECD patients disclosed thickening and nodularity of DM and loss of endothelial cells. Immunohistochemical staining of FECD DM for AGE, RAGE, and AGE-R3 showed an abundance of AGEs in the anterior portion of DM, mild positivity for RAGE, and moderate positivity for AGE-R3. Conclusions Tissue quality after DSEK is sufficient to allow detailed histopathologic analysis. The presence of AGEs, RAGE, and AGE-R3 in DM and corneal endothelium of FECD patients supports a link between accumulation of AGEs, oxidative stress, and corneal endothelial cell apoptosis in the pathogenesis of FECD.